Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2025-12-26 @ 3:15 AM
Study NCT ID:
NCT06202820
Status:
RECRUITING
Last Update Posted:
2025-08-11
First Post:
2024-01-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
CV CARE: CardioVascular Care in PC Patients
Sponsor:
Dana-Farber Cancer Institute
Organization:
Study Overview
Official Title:
CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients
Status:
RECRUITING
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants.
The name of the intervention used in this research study is:
CV Care (cardiovascular risk assessment and management program)
The name of the intervention used in this research study is:
CV Care (cardiovascular risk assessment and management program)
Detailed Description:
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants.
Study procedures including screening for eligibility, treatment visits, questionnaires and surveys, and blood and urine tests.
Participation in this research study is expected to last about 6 months.
It is expected that about 60-150 people will take part in this study.
This study is supported by the National Comprehensive Cancer Network (NCCN) through grant funding provided by Pfizer Myovant.
Study procedures including screening for eligibility, treatment visits, questionnaires and surveys, and blood and urine tests.
Participation in this research study is expected to last about 6 months.
It is expected that about 60-150 people will take part in this study.
This study is supported by the National Comprehensive Cancer Network (NCCN) through grant funding provided by Pfizer Myovant.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: